FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075496837> ?p ?o ?g. }

• W2075496837 endingPage "295" @default.
• W2075496837 startingPage "295" @default.
• W2075496837 abstract "Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study Norbert Marschner,1 Dirk Arnold,2 Erik Engel,3 Ulrich Hutzschenreuter,4 Jacqueline Rauh,5 Werner Freier,6 Holger Hartmann,7 Melanie Frank,8 Martina Jänicke7 On behalf of the TKK Registry Group 1Praxis für Interdisziplinäre Onkologie und Hämatologie, 2Klinik für Tumorbiologie, Freiburg, Germany; 3Hämatologisch – Onkologische Praxis Altona, Hamburg, Germany; 4Hämatologisch – Onkologische Gemeinschaftspraxis, Nordhorn, Germany; 5Fachinternistische Gemeinschaftspraxis und Therapiezentrum, Witten, Germany; 6Onkologische Praxis, Hildesheim, Germany; 7Clinical Epidemiology and Health Economics, iOMEDICO, 8Statistics, iOMEDICO, Freiburg, Germany Purpose: Several randomized trials investigating the preferable first-line combination chemotherapy regimen for metastatic colorectal cancer have shown inconsistent findings. Because a substantial number of patients are still being treated with "chemo-only" first-line therapies without targeted agents, we compared overall survival (OS) of patients treated in routine practice with oxaliplatin–fluoropyrimidine and irinotecan–fluoropyrimidine. Patients and methods: Using the database of the Tumor Registry Colorectal Cancer, we identified 605 patients with metastatic colorectal cancer who received first-line fluoropyrimidine combination chemotherapy with either oxaliplatin (n=430) or irinotecan (n=175). The Tumor Registry Colorectal Cancer is a cohort study that prospectively documents treatment of colorectal cancer by office-based medical oncologists in Germany and has recruited over 5,000 patients. OS was estimated using the Kaplan–Meier method, and a multivariate Cox proportional hazard model was used to adjust for potentially confounding variables. Results: Median OS was 26.8 (95% confidence interval [CI] 22.4–31.9) months with an oxaliplatin–fluoropyrimidine combination and 18.3 (95% CI 15.1–23.2) months with irinotecan–fluoropyrimidine first-line "chemo-only" therapy. Median progression-free survival was 9.0 (8.1–10.2) and 7.9 (7.2–10.2) months, respectively. The difference in OS was confirmed if analysis was restricted to patients with synchronous metastases (no prior treatment). Among other variables, proportion of patients receiving any second-line therapy did not differ between groups. Oxaliplatin-based first-line therapy was associated with improved OS in multivariate analysis adjusted for potentially confounding variables (hazard ratio 0.678, 95% CI 0.510–0.901, P=0.007). Conclusion: In clinical routine practice, first-line treatment with oxaliplatin–fluoropyrimidine combination chemotherapy compared to irinotecan–fluoropyrimidine combination is associated with improved survival in patients with metastatic colorectal cancer, independent of all examined potentially confounding factors. Keywords: colorectal neoplasms, epidemiology, irinotecan, oxaliplatin, cohort studies, treatment outcome" @default.
• W2075496837 created "2016-06-24" @default.
• W2075496837 creator A5015232096 @default.
• W2075496837 creator A5019964982 @default.
• W2075496837 creator A5025022333 @default.
• W2075496837 creator A5034764832 @default.
• W2075496837 creator A5037009390 @default.
• W2075496837 creator A5055362477 @default.
• W2075496837 creator A5059855685 @default.
• W2075496837 creator A5066665601 @default.
• W2075496837 creator A5091720515 @default.
• W2075496837 date "2015-04-01" @default.
• W2075496837 modified "2023-09-27" @default.
• W2075496837 title "Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer &ndash; Results from a prospective cohort study" @default.
• W2075496837 cites W1605571346 @default.
• W2075496837 cites W163580975 @default.
• W2075496837 cites W187777206 @default.
• W2075496837 cites W2000445173 @default.
• W2075496837 cites W2018571264 @default.
• W2075496837 cites W2028598260 @default.
• W2075496837 cites W2043318852 @default.
• W2075496837 cites W2059974369 @default.
• W2075496837 cites W2103789431 @default.
• W2075496837 cites W2112727687 @default.
• W2075496837 cites W2118592725 @default.
• W2075496837 cites W2125328045 @default.
• W2075496837 cites W2128403792 @default.
• W2075496837 cites W2133399075 @default.
• W2075496837 cites W2147041307 @default.
• W2075496837 cites W2151387711 @default.
• W2075496837 cites W2157416388 @default.
• W2075496837 cites W2161593277 @default.
• W2075496837 cites W2164906123 @default.
• W2075496837 cites W2170332580 @default.
• W2075496837 doi "https://doi.org/10.2147/clep.s73857" @default.
• W2075496837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4408959" @default.
• W2075496837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25945067" @default.
• W2075496837 hasPublicationYear "2015" @default.
• W2075496837 type Work @default.
• W2075496837 sameAs 2075496837 @default.
• W2075496837 citedByCount "14" @default.
• W2075496837 countsByYear W20754968372016 @default.
• W2075496837 countsByYear W20754968372017 @default.
• W2075496837 countsByYear W20754968372018 @default.
• W2075496837 countsByYear W20754968372019 @default.
• W2075496837 countsByYear W20754968372020 @default.
• W2075496837 countsByYear W20754968372021 @default.
• W2075496837 countsByYear W20754968372022 @default.
• W2075496837 countsByYear W20754968372023 @default.
• W2075496837 crossrefType "journal-article" @default.
• W2075496837 hasAuthorship W2075496837A5015232096 @default.
• W2075496837 hasAuthorship W2075496837A5019964982 @default.
• W2075496837 hasAuthorship W2075496837A5025022333 @default.
• W2075496837 hasAuthorship W2075496837A5034764832 @default.
• W2075496837 hasAuthorship W2075496837A5037009390 @default.
• W2075496837 hasAuthorship W2075496837A5055362477 @default.
• W2075496837 hasAuthorship W2075496837A5059855685 @default.
• W2075496837 hasAuthorship W2075496837A5066665601 @default.
• W2075496837 hasAuthorship W2075496837A5091720515 @default.
• W2075496837 hasBestOaLocation W20754968371 @default.
• W2075496837 hasConcept C121608353 @default.
• W2075496837 hasConcept C126322002 @default.
• W2075496837 hasConcept C143998085 @default.
• W2075496837 hasConcept C2776694085 @default.
• W2075496837 hasConcept C2778260052 @default.
• W2075496837 hasConcept C2778336483 @default.
• W2075496837 hasConcept C2780259306 @default.
• W2075496837 hasConcept C2780962732 @default.
• W2075496837 hasConcept C526805850 @default.
• W2075496837 hasConcept C71924100 @default.
• W2075496837 hasConceptScore W2075496837C121608353 @default.
• W2075496837 hasConceptScore W2075496837C126322002 @default.
• W2075496837 hasConceptScore W2075496837C143998085 @default.
• W2075496837 hasConceptScore W2075496837C2776694085 @default.
• W2075496837 hasConceptScore W2075496837C2778260052 @default.
• W2075496837 hasConceptScore W2075496837C2778336483 @default.
• W2075496837 hasConceptScore W2075496837C2780259306 @default.
• W2075496837 hasConceptScore W2075496837C2780962732 @default.
• W2075496837 hasConceptScore W2075496837C526805850 @default.
• W2075496837 hasConceptScore W2075496837C71924100 @default.
• W2075496837 hasLocation W20754968371 @default.
• W2075496837 hasLocation W20754968372 @default.
• W2075496837 hasLocation W20754968373 @default.
• W2075496837 hasLocation W20754968374 @default.
• W2075496837 hasOpenAccess W2075496837 @default.
• W2075496837 hasPrimaryLocation W20754968371 @default.
• W2075496837 hasRelatedWork W1952302484 @default.
• W2075496837 hasRelatedWork W1992982990 @default.
• W2075496837 hasRelatedWork W2043263760 @default.
• W2075496837 hasRelatedWork W2058385450 @default.
• W2075496837 hasRelatedWork W2072155890 @default.
• W2075496837 hasRelatedWork W2115466023 @default.
• W2075496837 hasRelatedWork W2169358424 @default.
• W2075496837 hasRelatedWork W2364734434 @default.
• W2075496837 hasRelatedWork W2412467430 @default.
• W2075496837 hasRelatedWork W2417717847 @default.
• W2075496837 isParatext "false" @default.
• W2075496837 isRetracted "false" @default.

• next